Pharmaceutical Giants Control the Insulin Market
In a shocking revelation, a new investigation has uncovered that three major pharmaceutical companies dominate 90% of the insulin market in the United States. This oligopoly has allowed them to coordinate price increases over the past decade, resulting in American patients paying 800% more for insulin than their counterparts in other countries. This is not just a financial crisis; it is a public health emergency.
Life-Saving Medication Becomes a Luxury
Insulin, a medication that costs approximately $3 to manufacture, has become a luxury item for many Americans. According to WH Herman, diabetic patients are now rationing their medication due to exorbitant prices, with some tragically succumbing to their conditions because they simply cannot afford this life-saving drug. This is a devastating indictment of a system that prioritizes profit over human life.
February 26, 2020 coronavirus news | CNN
Coordination of Price Increases Must Be Investigated
The coordinated price hikes by these pharmaceutical giants raise serious questions about market manipulation and anti-competitive practices. As reported by AW Mulcahy, the average gross prices for insulin in the U.S. are more than ten times higher than those in countries like France and the United Kingdom. This blatant disregard for patient welfare must be met with rigorous scrutiny and accountability.
Consequences of Insulin Rationing
The ramifications of insulin rationing are severe and far-reaching. A study from PubMed indicates that hospitalizations for complications related to diabetes have surged as a direct consequence of patients being forced to ration their insulin. Between 2009 and 2015, hospitalizations for diabetic ketoacidosis—a dangerous condition that can be fatal—rose alarmingly from 24.4 to 43.5 per 1,000 adults with diabetes. This trend is not just a statistic; it represents real lives, families, and futures at stake.
Diabetes Patients Pressure Drugmakers Over High Price Of ...
Pressure on Lawmakers to Act
Lawmakers must take immediate action to address this crisis. The time has come for comprehensive reforms that not only cap insulin prices but also break the monopolistic hold these companies have on the market. As emphasized by R Knox, barriers to competition must be dismantled to ensure that insulin is accessible and affordable for all Americans. The public outcry for change cannot be ignored.
Call to Action for Community Engagement
This is a moment for grassroots mobilization. Healthcare is a human right, and the continued exploitation of patients by pharmaceutical companies is intolerable. Communities must come together to demand action from their representatives, pushing for policies that prioritize affordable medication and health equity. Every voice counts in this critical fight for justice and dignity.
Boehringer replaces Bayer as Germany's largest drugmaker on ...
